Alembic Pharmaceuticals , a prominent player in the Indian pharmaceutical industry, has announced a significant change in its senior management. Mr. Shreekumar Nair, who held the position of President-Supply Chain Management and Operations, has retired from his role at the company.

Retirement Details

According to the official communication from Alembic Pharmaceuticals to the stock exchanges:

• Effective Date: Mr. Nair's cessation from his role took effect on July 31, 2025, after the closure of business hours.
• Reason for Change: The company cited superannuation as the reason for Mr. Nair's departure.

Company Disclosure

Alembic Pharmaceuticals made this announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the following details in its regulatory filing:

• The change in senior management personnel was officially communicated to both the BSE Limited and the National Stock Exchange of India Ltd.
• The company's filing included an annexure with specific details as required by SEBI regulations.

Impact and Future Steps

While the company has not provided information about a successor or the immediate plans for the Supply Chain Management and Operations department, such changes in senior management can be significant for a company's operations.

Alembic Pharmaceuticals, known for its presence in various pharmaceutical segments, will likely ensure a smooth transition in its supply chain and operations following Mr. Nair's retirement. The company's ability to manage this change effectively could be crucial for maintaining its operational efficiency and market position in the competitive pharmaceutical industry.

Alembic Pharmaceuticals Limited (APLLTD) has received a vote of confidence from CRISIL Ratings Limited, as the credit rating agency reaffirmed the company's AA+/Stable credit rating for its bank loan facilities. This development comes with an increase in the rated amount from Rs. 600.00 crores to Rs. 800.00 crores, while maintaining the company's overall borrowing limit.

Credit Rating Details

CRISIL Ratings Limited has provided the following rating for Alembic Pharmaceuticals:

The AA+ rating indicates a high degree of safety regarding timely servicing of financial obligations and very low credit risk. The 'Stable' outlook suggests that the rating is likely to remain unchanged in the medium term.

Implications of the Rating

The reaffirmation of the AA+/Stable rating reflects CRISIL's continued confidence in Alembic Pharmaceuticals' financial strength and stability. The enhancement of the rated amount from Rs. 600.00 crores to Rs. 800.00 crores, without changing the overall borrowing limit, suggests that the company has gained additional flexibility in its financing options.

Recent Developments

In addition to the credit rating news, Alembic Pharmaceuticals has recently achieved a significant milestone in its product portfolio. The company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP, in strengths of 100 mg, 200 mg, and 400 mg.

This approval is noteworthy as:

• The approved ANDA is therapeutically equivalent to Novartis Pharmaceuticals Corporation's Tegretol-XR Extended-Release Tablets.
• Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant and for treating pain associated with true trigeminal neuralgia.
• The estimated market size for these tablets is US$ 71.00 million for the twelve months ending March 2025, according to IQVIA data.

Company Profile

Alembic Pharmaceuticals Limited, founded in 1907, is a vertically integrated research and development pharmaceutical company. The company is publicly listed and specializes in manufacturing and marketing generic pharmaceutical products globally. With state-of-the-art research and manufacturing facilities approved by regulatory authorities of many developed countries, including the USFDA, Alembic Pharmaceuticals has established itself as a leader in branded generics in India.

The reaffirmation of its credit rating, along with the recent USFDA approval, underscores Alembic Pharmaceuticals' strong market position and its continued focus on growth and expansion in the pharmaceutical sector.